ArticleJournal of thoracic disease2026
Clinical characteristics and prognostic markers of anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease: a retrospective cohort study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis-associated interstitial lung disease (DM-ILD) is a severe condition with high mortality, often manifesting as rapidly progressive ILD (RP-ILD). This study aimed to explore potential clinical and laboratory variables associated with mortality in patients with anti-MDA5 + DM-ILD in a small exploratory cohort. Methods: We retrospectively analyzed 25 patients with anti-MDA5-positive DM-ILD admitted to our institution. Baseline clinical characteristics, imaging features, treatments, and laboratory parameters (collected upon admission) were evaluated. Univariable and multivariable Firth's penalized likelihood logistic regression models were utilized to identify risk factors for mortality. Results: The cohort included 6 males and 19 females (mean age 59.6±11.5 years). During the observation period, 16 patients survived and 9 died. Non-survivors exhibited significantly higher baseline levels of lactate dehydrogenase (LDH) (P=0.02) and D-dimer (P=0.03) compared to survivors. Univariable analysis indicated that both elevated LDH and D-dimer were associated with an increased risk of mortality. However, subsequent multivariable Firth regression analysis, adjusting for age, sex, and erythrocyte sedimentation rate (ESR), demonstrated that elevated baseline D-dimer was identified as a potential parameter associated with increased mortality [adjusted odds ratio (OR) =6.14, 95% confidence interval (CI): 1.69-135.73, P=0.003]. Conclusions: Baseline D-dimer elevation represents a potential prognostic indicator associated with poor survival in patients with anti-MDA5-positive DM-ILD. Assessing D-dimer levels upon admission provides crucial insights into the underlying severe vasculopathy, facilitating early risk stratification and the timely implementation of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.